CT-P13 SC (Infliximab)

( DrugBank: Infliximab / KEGG DRUG: Infliximab )

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	1

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2031200117	01/09/2020	11/09/2020	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Crohns Disease	Biological: CT-P13 SC (Infliximab) Other: Placebo SC	Ishida Tetsuya	Celltrion	Not Recruiting	>= 18age old	<= 75age old	Both	600	Phase 3	US;Latvia;Czech Republic;France;Poland;Germany;Greece;Hungary;Spain;Austria;Bulgaria;Croatia;Japan
2	NCT03945019 (ClinicalTrials.gov)	October 28, 2019	8/5/2019	CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn ...	A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Crohn's Disease	Biological: CT-P13 SC (Infliximab);Other: Placebo SC	Celltrion	NULL	Active, not recruiting	18 Years	75 Years	All	397	Phase 3	Poland;United States

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04205643 (ClinicalTrials.gov)	September 2, 2020	18/12/2019	CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcer ...	A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of ...	Ulcerative Colitis	Biological: CT-P13 SC (Infliximab);Other: Placebo SC	Celltrion	NULL	Active, not recruiting	18 Years	75 Years	All	548	Phase 3	Poland